Regulatory approval

Published by the Health Service Executive. Approved

Treatment of Non Hodgkins Lymphoma (NHL). Rituximab to be included in CD20 positive patients.

This is written in the approval document.

Reimbursement

Hospital

Citation

(*riTUXimab) cycloPHOSphamide, DOXOrubicin, vinCRIStine and prednisoLONE (*R)-CHOP) Therapy - 21 days, 2024, version number 5a, NCCP National SACT Regimen, viewed 26/03/2026, https://healthservice.hse.ie/documents/6711/307_v5a_R_Chop_21_days.pdf

View API

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations Biomarkers Cancer types Therapies
HSE (1) CD20 + Non-Hodgkin Lymphoma Cyclophosphamide, Doxorubicin, Prednisolone, Rituximab, Vincristine